Demographics, clinical characteristics, treatment (tx) patterns and clinical outcomes for patients ( pts) with limited-stage SCLC (LS-SCLC)

被引：0
|
作者：
Chiang, A. C. [1 ]
Salomonsen, R. J-B. [2 ]
Wang, A. [2 ]
Holland, R. [3 ]
Cai, L. [2 ]
Xiao, Y. [2 ]
Sadow, S. [2 ]
Davey, K. [3 ]
Iyengar, P. [4 ]
机构：
[1] Yale Univ, Sch Med, Thorac Oncol, New Haven, CT USA
[2] AstraZeneca, Gaithersburg, MD USA
[3] AstraZeneca, Cambridge, England
[4] UT Southwestern Med Ctr Dallas, Dallas, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168P
引用
收藏
页码：S132 / S133
页数：2
相关论文
共 50 条
  • [41] Evaluating the safety of using G-CSF prophylaxis during concurrent chemotherapy and thoracic irradiation in patients with limited-stage small-cell lung cancer (LS-SCLC): evidence from a phase II trial
    Colaco, Rovel J.
    Sheikh, Hamid Y.
    Ashcroft, Linda
    Blackhall, Fiona H.
    Lorigan, Paul C.
    Taylor, Paul
    Thatcher, Nicholas
    Faivre-Finn, Corinne
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S470 - S471
  • [42] Determination of Risk Factors Related to Supraclavicular Recurrence for Limited-Stage Small Cell Lung Cancer (SCLC) Patients
    Guan, Yong
    Zhang, Ximei
    MEDICAL SCIENCE MONITOR, 2019, 25 : 4968 - 4973
  • [43] Letter regarding "Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials"
    Li, Zheng
    Hu, Yue
    Li, Qiang
    RADIOTHERAPY AND ONCOLOGY, 2022, 177 : 243 - 244
  • [44] AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
    Lu, Y.
    Gong, Y.
    Kang, J-H.
    Ree, J. Whan
    Chen, X.
    Lin, X.
    Zhang, J.
    Borghaei, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S103 - S103
  • [45] Higher doses of thoracic radiation (TRT) are associated with improved overall survival in limited stage small cell lung cancer (LS-SCLC): an analysis of practice patterns at a Canadian regional cancer centre
    MacRae, Robert M.
    Giffin, Megan
    Laurie, Scott A.
    Nicholas, Garth
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S470 - S470
  • [46] Optimal timing of thoracic radiotherapy in limited stage small cell lung cancer (LS-SCLC) with daily fractionation: A national cancer database (NCDB) propensity matched analysis
    White, R.
    Hasan, S.
    Renz, P.
    Abel, S.
    Otaibi, Z.
    Colonias, A.
    Monga, D.
    Wegner, R. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 247 - 248
  • [47] Real world (rw) racial differences in treatment (tx) patterns and clinical outcomes among patients (pts) with mCRPC.
    Barata, Pedro C.
    Du, Ella X.
    Yang, Hongbo
    Xu, Chunyi
    Guo, Helen
    Cui, Caroline
    Nazari, Jonathan
    Niyazov, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [48] Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)
    Ding, Xiao-Long
    Su, Yi-Ge
    Yu, Liang
    Bai, Zhou-Lan
    Bai, Xue-Hong
    Chen, Xiao-Zhen
    Yang, Xia
    Zhao, Ren
    He, Jin-Xi
    Wang, Yan-Yang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [49] Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)
    Xiao-Long Ding
    Yi-Ge Su
    Liang Yu
    Zhou-Lan Bai
    Xue-Hong Bai
    Xiao-Zhen Chen
    Xia Yang
    Ren Zhao
    Jin-Xi He
    Yan-Yang Wang
    World Journal of Surgical Oncology, 20
  • [50] Extended-stage SCLC (ES-SCLC) patients treated with first-line chemotherapy plus atezolizumab in Spain: Characteristics and outcomes
    Gomez-Mugarza, P.
    Laguna, S.
    Zapata, M.
    Prado, L. Fernandez
    Gimeno, J.
    Nuno, A.
    Galan, N.
    Arnaiz, I. Gil
    Artal-Cortes, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S135 - S136
12345